Trial Profile
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 09 Feb 2010 Actual initiation date (Aug 2005) and actual patient number (57) added as reported by ClinicalTrials.gov.
- 09 Feb 2010 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 09 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.